Patents by Inventor Robin Robinson

Robin Robinson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Highly efficient influenza matrix (M1) proteins
    Patent number: 10544399
    Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: January 28, 2020
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Yingyun Wu, Michael J. Massare, Peter M. Pushko, Margaret Nathan, Thomas Kort, Robin Robinson
  • HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS
    Publication number: 20190062713
    Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
    Type: Application
    Filed: March 22, 2018
    Publication date: February 28, 2019
    Inventors: Gale SMITH, Yingyun WU, Michael J. MASSARE, Peter M. PUSHKO, Margaret NATHAN, Thomas KORT, Robin ROBINSON
  • Highly efficient influenza matrix (M1) proteins
    Patent number: 9951317
    Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: April 24, 2018
    Assignee: NOVAVAX, INC.
    Inventors: Gale Smith, Yingyun Wu, Michael J. Massare, Peter M. Pushko, Margaret Nathan, Thomas Kort, Robin Robinson
  • HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS
    Publication number: 20170253861
    Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
    Type: Application
    Filed: October 6, 2016
    Publication date: September 7, 2017
    Inventors: Gale SMITH, Yingyun WU, Michael J. MASSARE, Peter M. PUSHKO, Margaret NATHAN, Thomas KORT, Robin ROBINSON
  • Highly efficient influenza matrix (M1) proteins
    Patent number: 9464276
    Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: October 11, 2016
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Yingyun Wu, Michael Massare, Peter Pushko, Margaret Nathan, Thomas Kort, Robin Robinson
  • HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS
    Publication number: 20150307849
    Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
    Type: Application
    Filed: February 23, 2015
    Publication date: October 29, 2015
    Inventors: Gale SMITH, Yingyun WU, Michael MASSARE, Peter PUSHKO, Margaret NATHAN, Thomas KORT, Robin ROBINSON
  • Highly efficient influenza matrix (M1) proteins
    Patent number: 8992939
    Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
    Type: Grant
    Filed: October 24, 2011
    Date of Patent: March 31, 2015
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Yingyun Wu, Michael Massare, Peter Pushko, Margret Nathan, Thomas Kort, Robin Robinson
  • HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS
    Publication number: 20130039938
    Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
    Type: Application
    Filed: October 24, 2011
    Publication date: February 14, 2013
    Applicant: NOVAVAX, INC.
    Inventors: Gale SMITH, Yingyun Wu, Michael Massare, Peter Pushko, Margret Nathan, Thomas Kort, Robin Robinson
  • Functional influenza virus-like particles (VLPs)
    Publication number: 20060263804
    Abstract: Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations.
    Type: Application
    Filed: March 10, 2006
    Publication date: November 23, 2006
    Inventors: Robin Robinson, Peter Pushko
  • Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
    Publication number: 20050118191
    Abstract: Chimeric virus-like particles that exhibit conformational antigenic epitopes capable of eliciting neutralizing antibodies are disclosed herein. The chimeric virus-like particles of the invention comprise a recombinant viral capsid protein that encapsulates a recombinant viral protein during self-assembly into a chimeric virus-like particle, wherein the chimeric virus-like particle exhibits confirmational antigenic epitopes capable of eliciting neutralizing antibodies. Pharmaceutical compositions, vaccines, and diagnostic test kits containing the chimeric virus-particles are also provided.
    Type: Application
    Filed: August 13, 2004
    Publication date: June 2, 2005
    Inventors: Robin Robinson, Vittoria Cioce
  • Functional influenza virus-like particles (VLPs)
    Publication number: 20050009008
    Abstract: Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations.
    Type: Application
    Filed: July 11, 2003
    Publication date: January 13, 2005
    Inventors: Robin Robinson, Peter Pushko